Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H26O6 |
| Molecular Weight | 434.481 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=C(O)C(=CC=C1OCC2=CC=C(C=C2)[C@H](O)C3=CC(=CC=C3)C(O)=O)C(C)=O
InChI
InChIKey=DWQVYDLTPMGYNE-DEOSSOPVSA-N
InChI=1S/C26H26O6/c1-3-5-22-23(13-12-21(16(2)27)25(22)29)32-15-17-8-10-18(11-9-17)24(28)19-6-4-7-20(14-19)26(30)31/h4,6-14,24,28-29H,3,5,15H2,1-2H3,(H,30,31)/t24-/m0/s1
CNS Activity
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01184508
Phase 2 study in migraine prevention: 300 mg once daily, for 12 weeks
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Z572ZBT8XL
Created by
admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
|
PRIMARY | |||
|
889116-06-7
Created by
admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
|
PRIMARY | |||
|
LY-2300559
Created by
admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
|
PRIMARY | Official Title: A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study of LY2300559 in Patients With Migraine | ||
|
11611800
Created by
admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
|
PRIMARY | |||
|
DB13016
Created by
admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
|
PRIMARY |
ACTIVE MOIETY